The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Abstract
OBJECTIVE: There are significant unmet needs in the treatment of schizophrenia, especially for the treatment of cognitive impairment, negative syndrome, and cognitive function. Preclinical data suggest that agonists with selective affinity for acetylcholine muscarinic receptors provide a potentially new mechanism to treat schizophrenia. The authors studied xanomeline, a relatively selective muscarinic type 1 and type 4 (M(1) and M(4)) receptor agonist, to determine if this agent is effective in the treatment of schizophrenia. METHOD: In this pilot study, the authors examined the efficacy of xanomeline on clinical outcomes in subjects with schizophrenia (N=20) utilizing a double-blind, placebo-controlled, 4-week treatment design. Outcome measures included the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI) scale, and a test battery designed to measure cognitive function in patients with schizophrenia. RESULTS: Subjects treated with xanomeline did significantly better than subjects in the placebo group on total BPRS scores and total PANSS scores. In the cognitive test battery, subjects in the xanomeline group showed improvements most robustly in measures of verbal learning and short-term memory function. CONCLUSIONS: These results support further investigation of xanomeline as a novel approach to treating schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Sensorimotor Gating and Schizophrenia: Human and Animal Model Studies
Braff, D. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810140081011 · Cited by 1,309
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“Therefore, the need exists for novel therapeutic approaches, especially therapies that are effective in multiple domains of schizophrenia, particularly if they can have such effects via mechanisms other than the dopamine receptor blockade (7).”
BackgroundLevey, A., Kitt, C., Simonds, W., Price, D., & Brann, M. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-10-03218.1991 · Cited by 918
Mueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
Self-citationHaro, J. M., Kamath, S. A., Ochoa, S., Novick, D., Rele, K., Fargas, A., Rodríguez, M. J., Rele, R., Orta, J., Kharbeng, A., et al. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.107.s416.5.x · Cited by 656
Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice
Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., & Silva, A. J. (2003) · Nature Neuroscience · doi:10.1038/nn992 · Cited by 544
Marder, S. R., & Fenton, W. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.010 · Cited by 421
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Hamilton, S. E., Loose, M. D., Qi, M., Levey, A. I., Hille, B., McKnight, G. S., Idzerda, R. L., & Nathanson, N. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13311 · Cited by 366
Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice
Gomeza, J., Shannon, H., Kostenis, E., Felder, C., Zhang, L., Brodkin, J., Grinberg, A., Sheng, H., & Wess, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1692 · Cited by 348
Self-citationGomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Xia, B., Deng, C.-X., & Wess, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10483 · Cited by 322
Self-citationTherapeutic Opportunities for Muscarinic Receptors in the Central Nervous System
Felder, C. C., Bymaster, F. P., Ward, J., & DeLapp, N. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990607u · Cited by 235
Self-citationCrook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00918-5 · Cited by 228
Crook, J. M., Tomaskovic-Crook, E., Copolov, D. L., & Dean, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.918 · Cited by 227
Matsui, M., Motomura, D., Fujikawa, T., Jiang, J., Takahashi, S.-I., Manabe, T., & Taketo, M. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10627.2002 · Cited by 213
Yeomans, J. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00054-4 · Cited by 198
Tzavara, E. T., Bymaster, F. P., Davis, R. J., Wade, M. R., Perry, K. W., Wess, J., McKinzie, D. L., Felder, C., & Nomikos, G. G. (2004) · The FASEB Journal · doi:10.1096/fj.04-1575fje · Cited by 191
Self-citationXanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon, H. E., Bymaster, F. P., Calligaro, D. O., Greenwood, B., Mitch, C. H., Sawyer, B. D., Ward, J. S., Wong, D. T., Olesen, P. H., & Sheardown, M. J. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38667-2 · Cited by 186
Self-citationFriedman, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1794-x · Cited by 184
Harvey, P. D., Green, M. F., McGurk, S. R., & Meltzer, H. Y. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1342-5 · Cited by 156
The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat
Stanhope, K. J., Mirza, N. R., Bickerdike, M. J., Bright, J. L., Harrington, N. R., Hesselink, M. B., Kennett, G. A., Lightowler, S., Sheardown, M. J., Syed, R., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29291-0 · Cited by 142
The Brief Psychiatric Rating Scale
Andersen, J., Larsen, J. K., Schultz, V., Nielsen, B. M., Kørner, A., Behnke, K., Munk-Andersen, E., Butler, B., Allerup, P., & Bech, P. (2010) · Psychopathology · doi:10.1159/000284591 · Cited by 123 · cited 8×
“On day 11, after obtaining another ECG and BPRS and CGI scores, the dose of xanomeline and placebo were increased to 75 mg t.i.d and three tablets three times a day, respectively.”
MethodInfluentialMuscarinic cholinergic hyperactivity in schizophrenia
Tandon, R., Shipley, J. E., Greden, J. F., Mann, N. A., Eisner, W. H., & Goodson, J. A. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90006-d · Cited by 120
Andersen, M. B., Fink‐Jensen, A., Peacock, L., Gerlach, J., Bymaster, F. P., Lundbæk, J. A., & Werge, T. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300151 · Cited by 95
Self-citationRiemann, D. W., Hohagen, F., Krieger, S., Gann, H., Müller, W. E., Olbrich, R., Wark, H.-J., Bohus, M., Löw, H., & Berger, T. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90006-x · Cited by 83
Bymaster, F. P., & Felder, C. C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001019 · Cited by 75
Self-citationShannon, H. E., Hart, J. C., Bymaster, F. P., Calligaro, D. O., DeLapp, N. W., Mitch, C. H., Ward, J. S., Fink‐Jensen, A., Sauerberg, P., Jeppesen, L., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34979-1 · Cited by 73
Self-citationFunctional effects of the muscarinic receptor agonist, xanomeline, at 5‐HT1 and 5‐HT2 receptors
Watson, J. M., Brough, S., Coldwell, M. C., Gager, T., Ho, M., Hunter, A. J., Jerman, J. C., Middlemiss, D. N., Riley, G. J., & Brown, A. M. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702201 · Cited by 64
Perry, K. W., Nisenbaum, L. K., George, C., Shannon, H. E., Felder, C. C., & Bymaster, F. P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01017-9 · Cited by 56
Self-citationMuscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia
Dean, B., Crook, J. M., Pavey, G., Opeskin, K., & Copolov, D. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000684 · Cited by 54
Snyder, S. H. (1990) · Nature · doi:10.1038/347121a0 · Cited by 49
Research works printed but not linked: 4
- Delisi LE, Nasrallah HA: The CATIE schizophrenia effectiveness trial. Schizophr Res 2005; 80:v-vi · doi:10.1016/j.schres.2005.10.004
- 10.1001/archneurpsyc.1957.02330400066009 · doi:10.1001/archneurpsyc.1957.02330400066009
- 10.1038/sj.npp.1380235 · doi:10.1038/sj.npp.1380235 · Paper page
- Shannon HE, 1994, J Pharmacol Exp Ther, 269, 271
Cited by
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Schizophrenia, dopamine and the striatum: From biology to symptoms
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.004 · Cited by 763
“Encouragingly, a PAM of the M1/M4 receptor has shown efficacy in treating schizophrenia, although tolerability issues have prevented further clinical trials [116].”
BackgroundCognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Klinkenberg, I., & Blokland, A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.04.001 · Cited by 696
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Metadata
- Authors
- Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., & Felder, C. C.
- Venue
- American Journal of Psychiatry
- Published
- 2008-08
- Volume
- 165
- Issue
- 8
- Pages
- 1033-1039
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2081792830
- Cited by
- 560
- References
- 37
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.